-
Ultimovacs Receives Notice of Allowance on US Patent on Vaccine-Checkpoint Inhibitor Combinations
-
Ultimovacs ASA – Share Option Program
-
Ultimovacs ASA – Annual General Meeting held on 21 April 2022
-
Ultimovacs Presents TET Platform Pre-Clinical Data at AACR 2022 Supporting Clinical Development
-
Ultimovacs ASA – Disclosure of voting rights of Annual General Meeting
-
Ultimovacs to host Investor Days 2022: Meet the Team
-
Correction: Ultimovacs ASA: Annual Report 2021
-
Ultimovacs ASA: Notice of Annual General Meeting on 21 April 2022
-
Ultimovacs ASA: Annual Report 2021
-
Ultimovacs Hosting Key Opinion Leader Webinar on the Evolving Treatment Landscape of Melanoma
